FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048931162> ?p ?o ?g. }

• W3048931162 abstract "Combining targeted agents with adjuvant chemotherapy prolongs survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, but also increases the risk of adverse effects. The updated results of 3 randomized controlled trials (RCTs) were reported in 2019. Given the lack of adequate head-to-head pairwise assessment for anti-HER2 agents, network meta-analysis facilitates obtaining more precise inference for evidence-based therapy.RCTs comparing at least 2 anti-HER2 regimens in an adjuvant setting for HER2-positive early-stage breast cancer (EBC) were included. Hazard ratios for overall survival (OS) and disease free survival (DFS), with respective 95% confidence intervals were pooled for assessment of efficacy. A Bayesian statistical model was used, and odds ratios (ORs) for adverse events (AEs) were used to pool effect sizes.We demonstrated that 1-year trastuzumab plus chemotherapy had increased efficacy compared to shorter or longer treatment duration. The OR of cardiac events gradually increased from 6 months to 1 and 2-year trastuzumab arms, relative to chemotherapy only. Compared to trastuzumab plus chemotherapy, dual HER2-targeting therapies increased DFS, especially for hormone receptor negative patients. Dual anti-HER2 blockade regimens revealed an increased probability of gastrointestinal reactions. As a second agent, pertuzumab showed significantly higher DFS and OS.We conclude that 1-year adjuvant trastuzumab should remain as the standard treatment for HER2-positive EBC patients, as it has greater efficacy and a manageable proportion of AEs. Clinical efficacy can be increased for hormone receptor-negative tumors by including a second HER2-targeted agent to the treatment regimen. For hormone receptor-positive cases with basal disease, it is acceptable to reduce the risk of cardiotoxicity by shortening the duration of trastuzumab." @default.
• W3048931162 created "2020-08-18" @default.
• W3048931162 creator A5019614275 @default.
• W3048931162 creator A5025732261 @default.
• W3048931162 creator A5039496036 @default.
• W3048931162 creator A5040538229 @default.
• W3048931162 creator A5061209772 @default.
• W3048931162 creator A5075448214 @default.
• W3048931162 creator A5076977780 @default.
• W3048931162 creator A5084560885 @default.
• W3048931162 creator A5086686905 @default.
• W3048931162 creator A5087788392 @default.
• W3048931162 date "2020-01-01" @default.
• W3048931162 modified "2023-10-18" @default.
• W3048931162 title "Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer" @default.
• W3048931162 cites W1996778928 @default.
• W3048931162 cites W2034801324 @default.
• W3048931162 cites W2040935952 @default.
• W3048931162 cites W2095156669 @default.
• W3048931162 cites W2096818458 @default.
• W3048931162 cites W2098775844 @default.
• W3048931162 cites W2098923148 @default.
• W3048931162 cites W2100375606 @default.
• W3048931162 cites W2113144077 @default.
• W3048931162 cites W2130034035 @default.
• W3048931162 cites W2140354367 @default.
• W3048931162 cites W2146384083 @default.
• W3048931162 cites W2156677665 @default.
• W3048931162 cites W2175026167 @default.
• W3048931162 cites W2318605753 @default.
• W3048931162 cites W2461392364 @default.
• W3048931162 cites W2588681363 @default.
• W3048931162 cites W2588881638 @default.
• W3048931162 cites W2766460973 @default.
• W3048931162 cites W2768980003 @default.
• W3048931162 cites W2799775876 @default.
• W3048931162 cites W2883519239 @default.
• W3048931162 cites W2891944705 @default.
• W3048931162 cites W2897063983 @default.
• W3048931162 cites W2904779531 @default.
• W3048931162 cites W2925126067 @default.
• W3048931162 cites W2948720210 @default.
• W3048931162 cites W2948726637 @default.
• W3048931162 cites W2955928021 @default.
• W3048931162 doi "https://doi.org/10.4048/jbc.2020.23.e45" @default.
• W3048931162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7462812" @default.
• W3048931162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32908791" @default.
• W3048931162 hasPublicationYear "2020" @default.
• W3048931162 type Work @default.
• W3048931162 sameAs 3048931162 @default.
• W3048931162 citedByCount "0" @default.
• W3048931162 crossrefType "journal-article" @default.
• W3048931162 hasAuthorship W3048931162A5019614275 @default.
• W3048931162 hasAuthorship W3048931162A5025732261 @default.
• W3048931162 hasAuthorship W3048931162A5039496036 @default.
• W3048931162 hasAuthorship W3048931162A5040538229 @default.
• W3048931162 hasAuthorship W3048931162A5061209772 @default.
• W3048931162 hasAuthorship W3048931162A5075448214 @default.
• W3048931162 hasAuthorship W3048931162A5076977780 @default.
• W3048931162 hasAuthorship W3048931162A5084560885 @default.
• W3048931162 hasAuthorship W3048931162A5086686905 @default.
• W3048931162 hasAuthorship W3048931162A5087788392 @default.
• W3048931162 hasBestOaLocation W30489311621 @default.
• W3048931162 hasConcept C121608353 @default.
• W3048931162 hasConcept C126322002 @default.
• W3048931162 hasConcept C143998085 @default.
• W3048931162 hasConcept C197934379 @default.
• W3048931162 hasConcept C207103383 @default.
• W3048931162 hasConcept C2777329042 @default.
• W3048931162 hasConcept C2777863537 @default.
• W3048931162 hasConcept C2779786085 @default.
• W3048931162 hasConcept C2781164504 @default.
• W3048931162 hasConcept C44249647 @default.
• W3048931162 hasConcept C530470458 @default.
• W3048931162 hasConcept C71924100 @default.
• W3048931162 hasConceptScore W3048931162C121608353 @default.
• W3048931162 hasConceptScore W3048931162C126322002 @default.
• W3048931162 hasConceptScore W3048931162C143998085 @default.
• W3048931162 hasConceptScore W3048931162C197934379 @default.
• W3048931162 hasConceptScore W3048931162C207103383 @default.
• W3048931162 hasConceptScore W3048931162C2777329042 @default.
• W3048931162 hasConceptScore W3048931162C2777863537 @default.
• W3048931162 hasConceptScore W3048931162C2779786085 @default.
• W3048931162 hasConceptScore W3048931162C2781164504 @default.
• W3048931162 hasConceptScore W3048931162C44249647 @default.
• W3048931162 hasConceptScore W3048931162C530470458 @default.
• W3048931162 hasConceptScore W3048931162C71924100 @default.
• W3048931162 hasFunder F4320321001 @default.
• W3048931162 hasLocation W30489311621 @default.
• W3048931162 hasLocation W30489311622 @default.
• W3048931162 hasLocation W30489311623 @default.
• W3048931162 hasOpenAccess W3048931162 @default.
• W3048931162 hasPrimaryLocation W30489311621 @default.
• W3048931162 hasRelatedWork W10233532 @default.
• W3048931162 hasRelatedWork W13154270 @default.
• W3048931162 hasRelatedWork W16281497 @default.
• W3048931162 hasRelatedWork W16909223 @default.
• W3048931162 hasRelatedWork W2337926 @default.
• W3048931162 hasRelatedWork W2422317 @default.
• W3048931162 hasRelatedWork W4741852 @default.

• next